ABUS vs TROW · P/E 5.4, rev $6.2M vs P/E 12, rev $7.09B
Arbutus Biopharma Corp (ABUS) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the ABUS and TROW stock pages for the full models.
Not investment advice.